Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients

Stopped early · Not applicable

Conditions studied: Kidney Transplantation

In brief

The aim of this trial is to compare the safety and efficacy of a single dose of Thymoglobulin, rabbit derived antithymocyte globulin (Thymoglobulin, SangStat, Fremont, CA) to our standard four dose, four day Thymoglobulin induction regimen from the time of transplantation through a six month follow-up period. The primary endpoint will be the incidence of acute rejection. Secondary endpoints will include serious adverse events, evaluation of renal function, patient and graft survival, incidence of infectious complications, incidence of post-transplantation lymphoproliferative disorder (PTLD), duration and extent of lymphocyte depletion and immunoassays for evidence of recipient immune response to the allograft as well as duration of hospital stay.

Key facts

Study ID

NCT00235781

Run by

Washington University School of Medicine

People needed

90

Starts

2006-01-01

Expected to finish

2006-02-01

Last updated by the study team

2006-10-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients 18 years of age or older
• All consenting adult renal transplant recipients scheduled to receive induction therapy (deceased donor, living-related, or living-unrelated)
• Females of childbearing age must have a negative pregnancy test performed at the time of admission for transplantation
• Patient or guardian agrees to participate in the study and signs the informed consent.
• No known contraindication to the administration of Thymoglobulin

You may not qualify if…

• A known allergy to rabbit proteins or previous significant intolerance of Thymoglobulin administration
• Pregnant women or nursing mothers
• Patients with serological evidence of infection with HIV-1, human T-cell leukemia virus type 1 (HTLV-1), or the presence of serum hepatitis B surface antigen (HBsAg)
• Recipients of a human leukocyte antigen (HLA) identical living donor renal allograft (2-haplotype match)
• Recipients of simultaneous multiple organ transplantation
• Recipients with a pre-existing, non-renal, solid organ transplant
• Recipients of ≥2 previous renal allografts
• Patients with a history of malignancy with evidence of recurrence within 2 years (except adequately treated localized squamous or basal cell carcinoma of the skin).
• Any patient who, in the opinion of the investigator, has a significant medical or psychosocial problem that should preclude them from the study.

Where it is running

• Washington University School of Medicine/Barnes-Jewish Hospital — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.